^
Association details:
| Biomarker: | ALK rearrangement + TP53 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Alecensa (alectinib) (ALK inhibitor) + Ninlaro (ixazomib) (Proteasome inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression
Published date:
03/21/2021
Excerpt:
To examine the efficacy and feasibility of combination therapy with alectinib and ixazomib in ALK/TP53 comutated NSCLC cells in vivo, we treated immunodeficient mice bearing A925L tumor xenografts with alectinib or ixazomib monotherapy, or the combination therapy of both....combined alectinib and ixazomib therapy caused remarkable tumor shrinkage, and three of the eight tumors completely regressed (Fig. 5A; Supplementary Fig. S8A).
DOI:
10.1158/1078-0432.CCR-20-2853
